> Detailanzeige

Selden, Clare; Bundy, James; Erro, Eloy; Puschmann, Eva; Miller, Malcolm; Kahn, Delawir; Hodgson, Humphrey; Fuller, Barry; Gonzalez-Molina, Jordi; Le Lay, Aurelie; Gibbons, Stephanie; Chalmers, Sherri; Modi, Sunil; Thomas, Amy; Kilbride, Peter; Isaacs, Agnes; Ginsburg, Richard; Ilsley, Helen; Thomson, David; Chinnery, Galya; Mankahla, Ncedile; Loo, Lizel; Spearman, C. Wendy

A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure
  • Beteiligte: Selden, Clare; Bundy, James; Erro, Eloy; Puschmann, Eva; Miller, Malcolm; Kahn, Delawir; Hodgson, Humphrey; Fuller, Barry; Gonzalez-Molina, Jordi; Le Lay, Aurelie; Gibbons, Stephanie; Chalmers, Sherri; Modi, Sunil; Thomas, Amy; Kilbride, Peter; Isaacs, Agnes; Ginsburg, Richard; Ilsley, Helen; Thomson, David; Chinnery, Galya; Mankahla, Ncedile; Loo, Lizel; Spearman, C. Wendy
  • Erschienen: Springer Science and Business Media LLC, 2017
  • Erschienen in: Scientific Reports
  • Sprache: Englisch
  • DOI: 10.1038/s41598-017-15021-4
  • ISSN: 2045-2322
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Liver failure, whether arising directly from acute liver failure or from decompensated chronic liver disease is an increasing problem worldwide and results in many deaths. In the UK only 10% of individuals requiring a liver transplant receive one. Thus the need for alternative treatments is paramount. A BioArtificial Liver machine could temporarily replace the functions of the liver, buying time for the patient’s liver to repair and regenerate. We have designed, implemented and tested a clinical-scale BioArtificial Liver machine containing a biomass derived from a hepatoblastoma cell-line cultured as three dimensional organoids, using a fluidised bed bioreactor, together with single-use bioprocessing equipment, with complete control of nutrient provision with feedback BioXpert recipe processes, and yielding good phenotypic liver functions. The methodology has been designed to meet specifications for GMP production, required for manufacture of advanced therapy medicinal products (ATMPs). In a porcine model of severe liver failure, damage was assured in all animals by surgical ischaemia in pigs with human sized livers (1.2–1.6 kg liver weights). The BioArtificial liver (UCLBAL) improved important prognostic clinical liver-related parameters, eg, a significant improvement in coagulation, reduction in vasopressor requirements, improvement in blood pH and in parameters of intracranial pressure (ICP) and oxygenation.</jats:p>
  • Zugangsstatus: Freier Zugang